The time for investments in EM hard currency sovereign debt has not come yet

Despite a slight spread widening, EM hard currency sovereign bonds have yielded a strong return year-to-date – thanks to decreasing underlying yields. While capital inflows have subsided in recent weeks, the outlook, given the low yield environment, is rather positive going forward. Moreover, the limited financing needs in Q4 curtail the upcoming supply.

Highlights:

  • Despite a slight spread widening, EM hard currency sovereign bonds have yielded a strong return year-to-date – thanks to decreasing underlying yields.
  • While capital inflows have subsided in recent weeks, the outlook, given the low yield environment, is rather positive going forward. Moreover, the limited financing needs in Q4 curtail the upcoming supply.
  • However, persisting recession fears and political risks are expected to trigger somewhat higher spreads in the near term.
  • The outlook for 2020 is more constructive. A modest rebound of the world economy and a weakening USD are likely to contribute to a modest tightening of EM hard currency bond spreads.

Download the full publication below

THE TIME FOR INVESTMENTS IN EM HARD CURRENCY SOVEREIGN
DEBT HAS NOT COME
YET

MORE INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.